1-甲基-3-[4-(甲基氨基甲酰氨基)苯基]脲 | 94628-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-3-[4-(甲基氨基甲酰氨基)苯基]脲
• 英文名称: N,N'-Bis-methylcarbamoyl-p-phenylendiamin
• 英文别名: 1-Methyl-3-[4-(methylcarbamoylamino)phenyl]urea
• CAS: 94628-91-8
• 化学式: C₁₀H₁₄N₄O₂
• mdl: MFCD01456884
• 分子量: 222.247
• InChiKey: YNKFUFKMBLAHJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.3
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基-3-[4-(甲基氨基甲酰氨基)苯基]脲 在 甲酸 、 sodium nitrite 作用下， 生成 1,1'-p-phenylenebis(3-methyl-3-nitroso-urea)
  参考文献：
  名称：

  抗肿瘤剂的合成。XXXII。N-硝基 一世。

  摘要：

  DOI：

  10.1021/jm00342a010
• 作为产物：
  描述：

  异氰酸甲酯 、 对苯二胺 以 氯仿 为溶剂， 生成 1-甲基-3-[4-(甲基氨基甲酰氨基)苯基]脲
  参考文献：
  名称：

  抗肿瘤剂的合成。XXXII。N-硝基 一世。

  摘要：

  DOI：

  10.1021/jm00342a010

文献信息

• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100190784A1

  公开（公告）日：2010-07-29

  A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, R 1a , R 1b , R 2a , R 2b , U 1 , U 2 , X 1 , X 2 and L are as defined herein.

  化合物的式子（I），或其立体异构体或药学上可接受的盐，其中，R1a，R1b，R2a，R2b，U1，U2，X1，X2和L的定义如下。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Charmot Dominique

  公开号：US20120263670A1

  公开（公告）日：2012-10-18

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和方法，用于治疗与液体潴留或盐过载相关的疾病，如心力衰竭（特别是充血性心力衰竭）、慢性肾脏病、终末期肾脏病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂引起的液体潴留。本公开还涉及化合物和方法，用于治疗高血压。本公开还涉及化合物和方法，用于治疗胃肠道疾病，包括治疗或减轻与胃肠道疾病相关的疼痛。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER
  申请人：Ardelyx, Inc.

  公开号：US20150190389A1

  公开（公告）日：2015-07-09

  The present disclosure is directed to compounds of the structure (X): CoreL-NHE) n (X) wherein: n is 2 or 3; NHE has the structure wherein: R 1 is H or —SO 2 —NR 7 R 8 —; R 2 is selected from H, —NR 7 (CO)R 8 , —SO 2 —NR 7 R 8 — and —NR 7 R 8 ; R 3 is hydrogen; R 7 is hydrogen; R 8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(═O)—, —NHC(═O)NH— and —NHSO 2 —; and Y is selected from the group consisting of a bond, optionally substituted C 1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH 2 ) 1-6 O(CH 2 ) 1-6 —, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.

  本公开涉及结构为（X）：CoreL-NHE)n（X）的化合物，其中：n为2或3；NHE具有以下结构：其中：R1为H或—SO2—NR7R8—；R2选自H，—NR7（CO）R8，—SO2—NR7R8—和—NR7R8；R3为氢；R7为氢；R8为连接到L的键；L为多聚乙二醇连接剂；Core具有以下结构：其中：X选自由键，—O—，—NH—，NHC（═O）—，—NHC（═O）NH—和—NHSO2—；Y选自键，可选择性地取代的C1-6烷基，可选择性地取代的苯，吡啶基，聚乙二醇连接剂和—（CH2）1-6O（CH2）1-6—，以及使用这种化合物治疗肠易激综合征、慢性肾脏病和终末期肾脏疾病的方法。
• PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP3173408A1

  公开（公告）日：2017-05-31

  The present invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof which has an excellent NHE3 inhibitory effect:         [Formula 15]     A-Y [1] wherein A represents a structure represented by the following formula [2]: wherein R11 and R12 each represent a halogen atom or the like, R2 represents C1-6 alkyl or the like, ring E represents triazole, tetrazole, pyrimidine, or the like, R31 and R32 each represent a hydrogen atom, C1-6 alkyl, C1-6 alkoxy, or the like, and W represents a single bond, the formula -NH-, the formula -O-, or the formula -CONH-, and Y represents a hydrogen atom or a structure represented by the following formula [3']:

  本发明提供了由下式[1]代表的化合物或其药学上可接受的盐，该化合物具有极佳的 NHE3 抑制作用： [式 15] A-Y [1］ 其中 A 代表下式[2]所代表的结构： 其中 R11 和 R12 分别代表卤素原子或类似物、 R2 代表 C1-6 烷基或类似物、 环 E 代表三唑、四唑、嘧啶或类似物、 R31 和 R32 各自代表氢原子、C1-6 烷基、C1-6 烷氧基或类似物，以及 W 代表单键、式-NH-、式-O-或式-CONH-，以及 Y 代表氢原子或下式[3']所代表的结构：
• NHE3-BINDING COMPOUNDS FOR INHIBITING PHOSPHATE TRANSPORT
  申请人：Ardelyx, Inc.

  公开号：EP3552630A1

  公开（公告）日：2019-10-16

  Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.

  本文提供了具有磷酸盐转运抑制剂活性的 NHE3 结合剂和/或 NHE3 调节剂，包括胃肠道和肾脏磷酸盐转运抑制剂，以及将其用作治疗或预防剂的方法。

表征谱图